
Bayer proposes to buy radiopharmaceutical partner Algeta for $2.4bn; offer increased, finalized
Executive Summary
Bayer AG proposed to buy its radiopharmaceutical partner, publicly traded Algeta ASA, for NOK336 ($55.11) per share, a 27% premium, valuing Algeta at $2.4bn.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Radiopharmaceuticals, Contrast Agents
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Payment Includes Cash
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com